- Home
- AMSF vs MYGN Comparison
AMSF vs MYGN Comparison
Compare AMSF & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- MYGN
- Stock Information
- Founded
- AMSF 1985
- MYGN 1991
- Country
- AMSF United States
- MYGN United States
- Employees
- AMSF N/A
- MYGN N/A
- Industry
- AMSF Accident &Health Insurance
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AMSF Finance
- MYGN Health Care
- Exchange
- AMSF Nasdaq
- MYGN Nasdaq
- Market Cap
- AMSF 869.6M
- MYGN 744.7M
- IPO Year
- AMSF 2005
- MYGN 1995
- Fundamental
- Price
- AMSF $44.16
- MYGN $5.34
- Analyst Decision
- AMSF Buy
- MYGN Hold
- Analyst Count
- AMSF 2
- MYGN 15
- Target Price
- AMSF $59.50
- MYGN $15.14
- AVG Volume (30 Days)
- AMSF 140.5K
- MYGN 1.3M
- Earning Date
- AMSF 07-24-2025
- MYGN 08-05-2025
- Dividend Yield
- AMSF 10.35%
- MYGN N/A
- EPS Growth
- AMSF N/A
- MYGN N/A
- EPS
- AMSF 2.48
- MYGN N/A
- Revenue
- AMSF $301,216,000.00
- MYGN $831,300,000.00
- Revenue This Year
- AMSF $1.69
- MYGN N/A
- Revenue Next Year
- AMSF $6.54
- MYGN $6.68
- P/E Ratio
- AMSF $17.77
- MYGN N/A
- Revenue Growth
- AMSF N/A
- MYGN 7.38
- 52 Week Low
- AMSF $42.48
- MYGN $3.81
- 52 Week High
- AMSF $60.24
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- AMSF 47.66
- MYGN 50.85
- Support Level
- AMSF $42.80
- MYGN $4.90
- Resistance Level
- AMSF $44.19
- MYGN $5.83
- Average True Range (ATR)
- AMSF 0.91
- MYGN 0.28
- MACD
- AMSF 0.14
- MYGN 0.04
- Stochastic Oscillator
- AMSF 81.55
- MYGN 54.21
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.